Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -22.00K | -9.00K | 0.00 | 0.00 | 0.00 |
EBITDA | -70.24M | -52.39M | -60.56M | -27.33M | 8.42M |
Net Income | -67.76M | -45.39M | -60.36M | 3.55M | 8.42M |
Balance Sheet | |||||
Total Assets | 157.81M | 179.53M | 100.84M | 141.51M | 4.72M |
Cash, Cash Equivalents and Short-Term Investments | 154.49M | 176.50M | 99.81M | 13.79K | 4.72M |
Total Debt | 0.00 | 0.00 | 0.00 | 355.60K | 0.00 |
Total Liabilities | 18.70M | 19.51M | 21.29M | 14.82M | 39.00K |
Stockholders Equity | 125.91M | 146.81M | 59.33M | -32.06M | 4.68M |
Cash Flow | |||||
Free Cash Flow | -43.69M | -28.15M | -23.05M | -13.07M | -1.10M |
Operating Cash Flow | -43.57M | -28.08M | -15.05M | -1.07M | -1.10M |
Investing Cash Flow | -122.00K | -5.08M | -8.00M | -12.00M | -139.38M |
Financing Cash Flow | 9.74M | 109.84M | 121.29M | 355.60K | 141.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $210.46M | -1.27 | -58.95% | ― | -72.45% | -28.60% | |
49 Neutral | $111.59M | -9.84 | ― | ― | ― | 11.78% | |
43 Neutral | $262.67M | ― | -46.33% | ― | ― | -50.20% | |
36 Underperform | $118.35M | -4.07 | ― | ― | ― | -8.91% | |
35 Underperform | $104.79M | -1.46 | ― | ― | ― | 57.64% | |
30 Underperform | $179.07M | -2.62 | ― | ― | ― | -4.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.